Immuneering Corporation (IMRX) just reported positive results from the phase 1 portion of its phase 1/2 study using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Specifically, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback